CMMB

Chemomab Therapeutics

CMMB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,013

Bullish sentiment (50-day avg)78%

Price to earnings ratio-1.15

Market capitalization12M

Earnings per share-0.96

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-9M

Social

What share of all stock conversation is about CMMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 28

The merger between Chemomab Therapeutics Ltd. and Scipher is expected to be completed, with a PIPE financing of $30M, and possibly up to $50M, with the new company's cash burn set to be around $3M quarterly.
The S-4 Pro Forma Combined post-merger company has a NCAV floor of ~$2.15 PPS, making it oversold, in the opinion of one commentator.
The CEO of Chemomab is the only one continuing from the old company, with the rest of the board being replaced, and Scipher controlling everything in the new company, having sacrificed a lot on the deal, including $230M in cash spent on Scipher.

Generated by AI

Sentiment

Of the messages about CMMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +10	47.06% -26.27	58% -29.6	78.4% -0.78
Bearish	50% -10	52.94% +26.27	42% +29.6	21.6% +0.78

Bullish· Jul 8

The merger with Scipher Medicine will give Chemomab Therapeutics Ltd. a 32% stake in a company valued at $150 million, representing a significant increase in value from its current market capitalization.
The combined entity will have a revenue-generating business, a strong cash position, and a pipeline of products, including an AI-powered precision medicine platform, which is expected to drive growth and increase the company's valuation.
The merger will also provide Chemomab with a stronger negotiating position to secure partnerships for its PSC and SSC assets, and the company's management will have more resources to pursue these opportunities, potentially leading to a higher valuation for the company.

Bearish· Jul 8

The company's merger deal may be unfavorable, with some investors believing it undervalues the equity.
Retail investors may regret selling the stock at its current price, which is a fraction of its perceived value.
The lack of a partnership with a big pharma company is a significant disappointment, and may indicate a lack of confidence in the company's future prospects.

Generated by AI

Topics

Of the messages about CMMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	70.26%
Technical Analysis	0%	0%	0%	24.87%
Macro	0%	0%	0%	2.76%
Analysts	0%	0%	0%	0.66%
Controversies	0%	0%	0%	0.39%
Earnings	0%	0%	0%	1.05%

Announcements· Jul 8

The merger between Chemomab Therapeutics and Scipher Medicine values the combined company at $150 million, with Scipher Medicine contributing $102 million and Chemomab Therapeutics contributing $48 million.
The merged company will utilize Scipher's AI-powered precision medicine platform to advance Nebokitug in an AI-driven Phase 2 trial for rheumatoid arthritis, with a cash runway into H2 2028.
The merger was designed to protect shareholders' assets from dilution and new share issuances, ensuring their stake in the CM-101 program remains fixed until the drug reaches the market or is licensed/sold.

Technical Analysis· Nov 15

Chemomab Therapeutics Ltd. ($CMMB) is considered a potential buy with a VWAP breach, with a key level at $0.96.
The stock's price action is being monitored, with observations of lower highs on gap-up days and a potential double bottom formation.
Technical indicators such as the RSI and MACD are being used to identify potential support and resistance levels, with the 20 EMA on the 1-minute chart being used as support.

Generated by AI

Community

Of the messages about CMMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.62%	89.74%	92.68%	74.08%
Newcomers	15.38%	10.26%	7.32%	25.92%

Regulars· Sep 28

The merger between CMMB and Scipher has been completed, with Scipher controlling the new company and injecting $30-50 million in capital.
The FDA has raised the bar for approval, but the regulatory framework remains the same, and the conditions for approval have increased, which is a common occurrence in rare diseases.
The S-4 content has invalidated some theses, and the company may accept any offer, with the drug CM-101 having key advantages, including concentrated patient enrollment and easy treatment administration.

Newcomers· Nov 16

New traders are looking at Chemomab Therapeutics Ltd. as a potential trading opportunity, with one user sharing a successful trade involving the stock.
The company's recent FDA news is seen as a catalyst for further news releases, with one user noting a dip as a buying opportunity.
Short sellers are taking a cautious approach, with one user expressing surprise at the stock's price movement and another closing a short position pre-market, anticipating a potential bounce.

Generated by AI

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)

1d agoBenzinga

Chemomab at H.C. Wainwright conference: merger sets ra push

18d agoInvesting.com

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

29d agoYahoo Finance

Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations

Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with substantial unmet need—nebokitug could potentially be the first novel mechanism RA therapy approved in the U.S. since 2012 Scipher’s AI Network Medicine platform identified first-in-class CCL24-blocker nebokitug as the highest ranked clinical-stage candidate for RA, potentially providing

1mo agoYahoo Finance

Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow

2mo agoSeeking Alpha

Also Discussed

Investors talking about CMMB also mention

#	Name	Attention
1	Alset Inc.AEI	0%0
2	WISeKey International Holding Ltd. ADRWKEY	0%0
3	Pop Culture Group Co., Ltd. Class A Ordinary SharesCPOP	0%new
4	ImageneBio, Inc.IKNA	0%0
5	China Liberal Education Holdings LimitedCLEU	0%new
6	EpicQuest Education Group International LimitedEEIQ	0%0
7	TIRX - Tian Ruixiang Holdings Ltd	——
8	Applied UV, Inc.AUVI	0%0
9	Enveric Biosciences Inc.ENVB	0%0
10	VERY - Vericity, Inc.	——

Chemomab Therapeutics Ltd. American Depositary Shares

Healthcare
Biotechnology

Chemomab Therapeutics Ltd. American Depositary Shares is the publicly traded ADR representation of Chemomab Therapeutics Ltd., a clinical-stage biotechnology company focused on developing therapies for fibro-inflammatory diseases. The company’s work centers on antibody-based treatments designed to address conditions involving inflammation and fibrosis, with a primary emphasis on areas of high unmet medical need such as liver, skin, and lung disorders. Chemomab Therapeutics Ltd. operates as a research-driven biopharmaceutical business, advancing product candidates through clinical development and working to translate its science into potential disease-modifying treatments. Its market role is that of a specialized biotech issuer within the healthcare sector, giving investors access to a company centered on novel therapeutic research rather than commercial-scale drug sales. The asset name, Chemomab Therapeutics Ltd. American Depositary Shares, reflects its U.S.-traded structure while representing the company’s ordinary shares.

Website

Location

Building C

Tel Aviv-Yafo, 6158101

Israel

Social

What share of all stock conversation is about CMMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 28

The merger between Chemomab Therapeutics Ltd. and Scipher is expected to be completed, with a PIPE financing of $30M, and possibly up to $50M, with the new company's cash burn set to be around $3M quarterly.
The S-4 Pro Forma Combined post-merger company has a NCAV floor of ~$2.15 PPS, making it oversold, in the opinion of one commentator.
The CEO of Chemomab is the only one continuing from the old company, with the rest of the board being replaced, and Scipher controlling everything in the new company, having sacrificed a lot on the deal, including $230M in cash spent on Scipher.

Generated by AI

Sentiment

Of the messages about CMMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +10	47.06% -26.27	58% -29.6	78.4% -0.78
Bearish	50% -10	52.94% +26.27	42% +29.6	21.6% +0.78

Bullish· Jul 8

The merger with Scipher Medicine will give Chemomab Therapeutics Ltd. a 32% stake in a company valued at $150 million, representing a significant increase in value from its current market capitalization.
The combined entity will have a revenue-generating business, a strong cash position, and a pipeline of products, including an AI-powered precision medicine platform, which is expected to drive growth and increase the company's valuation.
The merger will also provide Chemomab with a stronger negotiating position to secure partnerships for its PSC and SSC assets, and the company's management will have more resources to pursue these opportunities, potentially leading to a higher valuation for the company.

Bearish· Jul 8

The company's merger deal may be unfavorable, with some investors believing it undervalues the equity.
Retail investors may regret selling the stock at its current price, which is a fraction of its perceived value.
The lack of a partnership with a big pharma company is a significant disappointment, and may indicate a lack of confidence in the company's future prospects.

Generated by AI

Topics

Of the messages about CMMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	70.26%
Technical Analysis	0%	0%	0%	24.87%
Macro	0%	0%	0%	2.76%
Analysts	0%	0%	0%	0.66%
Controversies	0%	0%	0%	0.39%
Earnings	0%	0%	0%	1.05%

Announcements· Jul 8

The merger between Chemomab Therapeutics and Scipher Medicine values the combined company at $150 million, with Scipher Medicine contributing $102 million and Chemomab Therapeutics contributing $48 million.
The merged company will utilize Scipher's AI-powered precision medicine platform to advance Nebokitug in an AI-driven Phase 2 trial for rheumatoid arthritis, with a cash runway into H2 2028.
The merger was designed to protect shareholders' assets from dilution and new share issuances, ensuring their stake in the CM-101 program remains fixed until the drug reaches the market or is licensed/sold.

Technical Analysis· Nov 15

Chemomab Therapeutics Ltd. ($CMMB) is considered a potential buy with a VWAP breach, with a key level at $0.96.
The stock's price action is being monitored, with observations of lower highs on gap-up days and a potential double bottom formation.
Technical indicators such as the RSI and MACD are being used to identify potential support and resistance levels, with the 20 EMA on the 1-minute chart being used as support.

Generated by AI

Community

Of the messages about CMMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	84.62%	89.74%	92.68%	74.08%
Newcomers	15.38%	10.26%	7.32%	25.92%

Regulars· Sep 28

The merger between CMMB and Scipher has been completed, with Scipher controlling the new company and injecting $30-50 million in capital.
The FDA has raised the bar for approval, but the regulatory framework remains the same, and the conditions for approval have increased, which is a common occurrence in rare diseases.
The S-4 content has invalidated some theses, and the company may accept any offer, with the drug CM-101 having key advantages, including concentrated patient enrollment and easy treatment administration.

Newcomers· Nov 16

New traders are looking at Chemomab Therapeutics Ltd. as a potential trading opportunity, with one user sharing a successful trade involving the stock.
The company's recent FDA news is seen as a catalyst for further news releases, with one user noting a dip as a buying opportunity.
Short sellers are taking a cautious approach, with one user expressing surprise at the stock's price movement and another closing a short position pre-market, anticipating a potential bounce.

Generated by AI

Chemomab Therapeutics

Social

Sep 28

Bullish· Jul 8

Bearish· Jul 8

Announcements· Jul 8

Technical Analysis· Nov 15

Regulars· Sep 28

Newcomers· Nov 16

12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

Chemomab at H.C. Wainwright conference: merger sets ra push

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow

Also Discussed

Chemomab Therapeutics Ltd. American Depositary Shares

Company Information

Location

12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

Chemomab at H.C. Wainwright conference: merger sets ra push

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow

Also Discussed

Social

Sep 28

Bullish· Jul 8

Bearish· Jul 8

Announcements· Jul 8

Technical Analysis· Nov 15

Regulars· Sep 28

Newcomers· Nov 16